8-K Announcements
6Material company update
Apr 29, 2026·SEC
Material company update
Apr 8, 2026·SEC
Material company update
Jan 30, 2026·SEC
Regeneron Pharmaceuticals, Inc.(REGN)Earnings, Financials & Key Ratios
REGN•NASDAQ
$720.78
$74.89B mkt cap·17.4× P/E·Price updated May 6, 2026
AboutRegeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.Show more
- Revenue$14.34B+1.0%
- EBITDA$4.12B-7.9%
- Net Income$4.5B+2.1%
- EPS (Diluted)41.48+8.2%
- Gross Margin85.35%-0.9%
- EBITDA Margin28.74%-8.8%
- Operating Margin24.95%-11.2%
- Net Margin31.41%+1.1%
- ROE14.87%-6.8%
- ROIC8.88%-17.6%
- Debt/Equity0.09-6.0%
- Interest Coverage120.42+37.5%
REGN Key Insights
Regeneron Pharmaceuticals, Inc. (REGN) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓FCF machine: 28.4% free cash flow margin
- ✓Strong 5Y sales CAGR of 11.0%
- ✓Good 3Y average ROE of 15.7%
- ✓Share count reduced 5.6% through buybacks
- ✓Healthy 5Y average net margin of 35.7%
✗Weaknesses
No significant weaknesses identified
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
REGN Price & Volume
Regeneron Pharmaceuticals, Inc. (REGN) stock price & volume — 10-year historical chart
Loading chart...
REGN Growth Metrics
Regeneron Pharmaceuticals, Inc. (REGN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years13.33%
5 Years11.04%
3 Years5.62%
TTM5.92%
Profit CAGR
10 Years21.62%
5 Years5.1%
3 Years1.26%
TTM-1.69%
EPS CAGR
10 Years22.35%
5 Years6.33%
3 Years2.77%
TTM4.48%
Return on Capital
10 Years24.1%
5 Years22.16%
3 Years12.8%
Last Year10.22%
REGN Recent Earnings
Regeneron Pharmaceuticals, Inc. (REGN) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 10/12 qtrs (83%)●Beat Revenue 10/12 qtrs (83%)
Q2 2026Latest
Apr 29, 2026EPS
$9.47
Est $8.91
+6.3%
Revenue
$3.6B
Est $3.5B
+3.6%
Q1 2026
Jan 30, 2026EPS
$11.44
Est $10.74
+6.5%
Revenue
$3.9B
Est $3.8B
+1.9%
Q4 2025
Oct 28, 2025EPS
$11.83
Est $9.65
+22.6%
Revenue
$3.8B
Est $3.6B
+4.5%
Q3 2025
Aug 1, 2025EPS
$12.89
Est $8.43
+52.9%
Revenue
$3.7B
Est $3.3B
+11.8%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 29, 2026 | $9.47vs $8.91+6.3% | $3.6Bvs $3.5B+3.6% |
| Q1 2026 | Jan 30, 2026 | $11.44vs $10.74+6.5% | $3.9Bvs $3.8B+1.9% |
| Q4 2025 | Oct 28, 2025 | $11.83vs $9.65+22.6% | $3.8Bvs $3.6B+4.5% |
| Q3 2025 | Aug 1, 2025 | $12.89vs $8.43+52.9% | $3.7Bvs $3.3B+11.8% |
Based on last 12 quarters of dataView full earnings history →
REGN Peer Comparison
Regeneron Pharmaceuticals, Inc. (REGN) competitors in Drug Discovery and Antibody Platforms — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 BIIB | 28.15B | 190.68 | 21.59 | 1.39% | 13.92% | 7.55% | 0.38 | |
 VRTX | 108.78B | 427.65 | 27.91 | 9.57% | 35.4% | 23.93% | 0.21 | |
 INCY | 19.95B | 99.85 | 15.58 | 21.22% | 26.71% | 29.31% | 0.01 | |
 BMRN | 10.5B | 54.60 | 30.33 | 12.87% | 8.29% | 4.41% | 0.11 | |
 ABBV | 362.56B | 204.98 | 86.49 | 8.57% | 6.91% | 62.15% | ||
 LLY | 932.64B | 987.11 | 43.01 | 44.7% | 34.98% | 101.17% | 1.60 | |
 AMGN | 178.7B | 331.11 | 23.27 | 9.92% | 20.95% | 89.41% | 6.31 | |
 GILD | 169.83B | 136.30 | 358.68 | 6.04% | 28.9% | 37.62% | 1.39 |
Compare REGN vs Peers
Regeneron Pharmaceuticals, Inc. (REGN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
REGN Income Statement
Regeneron Pharmaceuticals, Inc. (REGN) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 5.87B | 6.71B | 6.56B | 8.5B | 16.07B | 12.17B | 13.12B | 14.2B | 14.34B | 14.92B |
| Revenue Growth % | 20.82% | 14.28% | -2.28% | 29.58% | 89.14% | -24.26% | 7.76% | 8.27% | 0.99% | 5.92% |
| Cost of Goods Sold | 542.53M | 582.3M | 975.4M | 1.36B | 2.72B | 1.71B | 2.24B | 1.97B | 2.1B | 2.31B |
| COGS % of Revenue | 9.24% | 8.68% | 14.87% | 15.96% | 16.95% | 14.01% | 17.11% | 13.87% | 14.65% | - |
| Gross Profit | 5.33B▲ 0% | 6.13B▲ 15.0% | 5.58B▼ 8.9% | 7.14B▲ 27.9% | 13.35B▲ 86.9% | 10.47B▼ 21.6% | 10.87B▲ 3.9% | 12.23B▲ 12.5% | 12.24B▲ 0.1% | 12.61B▲ 0% |
| Gross Margin % | 90.76% | 91.32% | 85.13% | 84.04% | 83.05% | 85.99% | 82.89% | 86.13% | 85.35% | 84.55% |
| Gross Profit Growth % | 19.61% | 14.99% | -8.91% | 27.93% | 86.91% | -21.58% | 3.87% | 12.5% | 0.09% | - |
| Operating Expenses | 3.25B | 3.59B | 3.37B | 3.56B | 4.4B | 5.08B | 6.52B | 8.24B | 8.66B | 8.98B |
| OpEx % of Revenue | 55.35% | 53.56% | 51.43% | 41.95% | 27.38% | 41.75% | 49.74% | 58.03% | 60.41% | - |
| Selling, General & Admin | 1.32B | 1.56B | 1.34B | 1.35B | 1.82B | 2.12B | 2.54B | 2.95B | 2.7B | 2.71B |
| SG&A % of Revenue | 22.49% | 23.19% | 20.46% | 15.84% | 11.35% | 17.38% | 19.36% | 20.8% | 18.82% | - |
| Research & Development | 1.93B | 2.04B | 2.24B | 2.5B | 2.62B | 3.06B | 3.99B | 5.23B | 5.85B | 6.26B |
| R&D % of Revenue | 32.86% | 30.37% | 34.15% | 29.41% | 16.31% | 25.11% | 30.39% | 36.85% | 40.79% | - |
| Other Operating Expenses | 0 | 0 | -209.2M | -280.4M | -45.6M | -89.9M | -2.1M | 53.4M | 114.1M | 0 |
| Operating Income | 2.08B▲ 0% | 2.53B▲ 21.9% | 2.21B▼ 12.8% | 3.58B▲ 61.9% | 8.95B▲ 150.1% | 5.39B▼ 39.8% | 4.35B▼ 19.3% | 3.99B▼ 8.2% | 3.58B▼ 10.3% | 3.63B▲ 0% |
| Operating Margin % | 35.41% | 37.77% | 33.7% | 42.09% | 55.67% | 44.24% | 33.15% | 28.1% | 24.95% | 24.32% |
| Operating Income Growth % | 56.27% | 21.87% | -12.81% | 61.85% | 150.15% | -39.8% | -19.26% | -8.23% | -10.34% | - |
| EBITDA | 2.23B | 2.68B | 2.42B | 3.81B | 9.23B | 5.73B | 4.77B | 4.47B | 4.12B | 4.17B |
| EBITDA Margin % | 37.89% | 39.97% | 36.91% | 44.87% | 57.45% | 47.05% | 36.36% | 31.5% | 28.74% | 27.94% |
| EBITDA Growth % | 55% | 20.56% | -9.79% | 57.53% | 142.18% | -37.97% | -16.72% | -6.21% | -7.87% | -3.64% |
| D&A (Non-Cash Add-back) | 145.47M | 148.2M | 210.3M | 235.9M | 286.2M | 341.4M | 421M | 482.9M | 543.7M | 540M |
| EBIT | 2.1B | 2.58B | 2.46B | 3.87B | 9.38B | 4.92B | 4.27B | 4.84B | 5.27B | 5.2B |
| Net Interest Income | -25.12M | -28.2M | -30.2M | -56.9M | -57.3M | 100.7M | 422.9M | 656.2M | 673M | 678.7M |
| Interest Income | 0 | 0 | 0 | 0 | 0 | 160.1M | 495.9M | 711.4M | 716.8M | 726.7M |
| Interest Expense | 25.12M | 28.2M | 30.2M | 56.9M | 57.3M | 59.4M | 73M | 55.2M | 43.8M | 48M |
| Other Income/Expense | -1.08M | 19.1M | 219.3M | 233.8M | 379M | -526.8M | -149.3M | 789.2M | 1.65B | 1.53B |
| Pretax Income | 2.08B▲ 0% | 2.55B▲ 22.9% | 2.43B▼ 4.9% | 3.81B▲ 56.9% | 9.33B▲ 144.7% | 4.86B▼ 47.9% | 4.2B▼ 13.6% | 4.78B▲ 13.8% | 5.23B▲ 9.4% | 5.16B▲ 0% |
| Pretax Margin % | 35.4% | 38.05% | 37.04% | 44.84% | 58.03% | 39.91% | 32.01% | 33.66% | 36.47% | 34.56% |
| Income Tax | 880M | 109.1M | 313.3M | 297.2M | 1.25B | 520.4M | 245.7M | 367.3M | 725.8M | 733.5M |
| Effective Tax Rate % | 42.34% | 4.27% | 12.9% | 7.8% | 13.41% | 10.71% | 5.85% | 7.68% | 13.88% | 14.22% |
| Net Income | 1.2B▲ 0% | 2.44B▲ 104.0% | 2.12B▼ 13.4% | 3.51B▲ 66.0% | 8.08B▲ 129.9% | 4.34B▼ 46.3% | 3.95B▼ 8.9% | 4.41B▲ 11.6% | 4.5B▲ 2.1% | 4.42B▲ 0% |
| Net Margin % | 20.41% | 36.42% | 32.26% | 41.35% | 50.25% | 35.64% | 30.14% | 31.07% | 31.41% | 29.65% |
| Net Income Growth % | 33.83% | 103.95% | -13.44% | 66.05% | 129.86% | -46.28% | -8.87% | 11.61% | 2.09% | -1.69% |
| Net Income (Continuing) | 1.2B | 2.44B | 2.12B | 3.51B | 8.08B | 4.34B | 3.95B | 4.41B | 4.5B | 4.42B |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | 10.34▲ 0% | 21.29▲ 105.9% | 18.46▼ 13.3% | 30.52▲ 65.3% | 71.97▲ 135.8% | 38.22▼ 46.9% | 34.77▼ 9.0% | 38.34▲ 10.3% | 41.48▲ 8.2% | 41.07▲ 0% |
| EPS Growth % | 34.29% | 105.9% | -13.29% | 65.33% | 135.81% | -46.89% | -9.03% | 10.27% | 8.19% | 4.48% |
| EPS (Basic) | 11.27 | 21.29 | 19.38 | 32.65 | 76.40 | 40.51 | 37.05 | 40.90 | 43.07 | - |
| Diluted Shares Outstanding | 115.91M | 114.8M | 114.6M | 115.1M | 112.2M | 113.5M | 113.7M | 115.1M | 108.6M | 107.7M |
| Basic Shares Outstanding | 115.9M | 114.8M | 109.2M | 107.6M | 105.7M | 107.1M | 106.7M | 107.9M | 104.6M | 104M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | 8.22% | - |
REGN Balance Sheet
Regeneron Pharmaceuticals, Inc. (REGN) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 5.6B | 7.96B | 7.69B | 9.78B | 14.01B | 15.88B | 19.48B | 18.66B | 18.02B | 18.21B |
| Cash & Short-Term Investments | 1.41B | 2.81B | 3.21B | 3.59B | 5.69B | 7.74B | 10.84B | 9.01B | 8.61B | 8.75B |
| Cash Only | 812.73M | 1.47B | 1.62B | 2.19B | 2.89B | 3.11B | 2.73B | 2.49B | 3.12B | 2.96B |
| Short-Term Investments | 596.85M | 1.34B | 1.6B | 1.39B | 2.81B | 4.64B | 8.11B | 6.52B | 5.49B | 5.79B |
| Accounts Receivable | 1.97B | 2.24B | 2.79B | 4.11B | 6.04B | 5.33B | 5.67B | 6.21B | 5.74B | 5.73B |
| Days Sales Outstanding | 122.72 | 122.01 | 155.05 | 176.75 | 137.09 | 159.78 | 157.7 | 159.65 | 146.1 | 139.26 |
| Inventory | 726.14M | 1.15B | 1.42B | 1.92B | 1.95B | 2.4B | 2.58B | 3.09B | 3.2B | 3.1B |
| Days Inventory Outstanding | 488.53 | 721.6 | 529.69 | 515.98 | 261.49 | 514.13 | 419.64 | 571.87 | 556.14 | 505.14 |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 386.6M | 349.2M | 474.8M | 0 |
| Total Non-Current Assets | 4.43B | 5.29B | 7.12B | 7.38B | 11.42B | 13.33B | 13.6B | 19.1B | 22.54B | 22.66B |
| Property, Plant & Equipment | 2.36B | 2.58B | 2.89B | 3.22B | 3.48B | 3.76B | 4.15B | 4.6B | 5.12B | 5.27B |
| Fixed Asset Turnover | 2.49x | 2.61x | 2.27x | 2.64x | 4.62x | 3.23x | 3.16x | 3.09x | 2.80x | 2.95x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 6.7M | 915.5M | 1.04B | 1.15B | 1.26B | 1.29B |
| Long-Term Investments | 1.49B | 1.75B | 3.26B | 3.14B | 6.84B | 6.59B | 5.4B | 8.9B | 10.26B | 40.39B |
| Other Non-Current Assets | 77.9M | 127.4M | 144.7M | 168.1M | 216.1M | 336.4M | 444.1M | 1.14B | 1.82B | 7.16B |
| Total Assets | 8.76B▲ 0% | 11.73B▲ 33.9% | 14.81B▲ 26.2% | 17.16B▲ 15.9% | 25.43B▲ 48.2% | 29.21B▲ 14.9% | 33.08B▲ 13.2% | 37.76B▲ 14.1% | 40.56B▲ 7.4% | 40.87B▲ 0% |
| Asset Turnover | 0.67x | 0.57x | 0.44x | 0.50x | 0.63x | 0.42x | 0.40x | 0.38x | 0.35x | 0.37x |
| Asset Growth % | 25.68% | 33.89% | 26.17% | 15.93% | 48.19% | 14.86% | 13.23% | 14.14% | 7.41% | 29.46% |
| Total Current Liabilities | 1.14B | 1.44B | 2.1B | 2.7B | 3.93B | 3.14B | 3.42B | 3.94B | 4.37B | 5.11B |
| Accounts Payable | 178.2M | 218.2M | 418.1M | 475.5M | 564M | 589.2M | 606.6M | 789.5M | 939M | 1.03B |
| Days Payables Outstanding | 119.89 | 136.77 | 156.46 | 128.01 | 75.58 | 126.12 | 98.65 | 146.24 | 163.15 | 142.22 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 320.14M | 452.5M | 591.7M | 577.7M | 442M | 477.9M | 458.9M | 627.7M | 553M | 2.22B |
| Other Current Liabilities | 0 | 0 | 85M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Ratio | 4.93x | 5.52x | 3.67x | 3.63x | 3.56x | 5.06x | 5.69x | 4.73x | 4.13x | 4.13x |
| Quick Ratio | 4.29x | 4.72x | 2.99x | 2.91x | 3.07x | 4.29x | 4.94x | 3.95x | 3.39x | 3.39x |
| Cash Conversion Cycle | 491.36 | 706.83 | 528.28 | 564.71 | 323 | 547.79 | 478.69 | 585.28 | 539.09 | 502.18 |
| Total Non-Current Liabilities | 1.48B | 1.53B | 1.62B | 3.44B | 2.73B | 3.41B | 3.68B | 4.46B | 4.93B | 4.34B |
| Long-Term Debt | 0 | 0 | 0 | 1.98B | 1.98B | 1.98B | 1.98B | 1.98B | 1.99B | 1.99B |
| Capital Lease Obligations | 703.5M | 708.5M | 713.9M | 717.2M | 0 | 720M | 720M | 720M | 720M | 2.16B |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 949.29M | 546.6M | 799.7M | 687.1M | 680.2M | 638M | 854.1M | 1.57B | 2.02B | 7.71B |
| Total Liabilities | 2.62B | 2.98B | 3.72B | 6.14B | 6.67B | 6.55B | 7.11B | 8.41B | 9.3B | 9.45B |
| Total Debt | 703.45M | 708.5M | 713.9M | 2.7B | 2.7B | 2.7B | 2.7B | 2.7B | 2.71B | 2.71B |
| Net Debt | -109.28M | -759.2M | -903.9M | 502M | -185.9M | -404.5M | -27.1M | 216.2M | -412.2M | -256.4M |
| Debt / Equity | 0.11x | 0.08x | 0.06x | 0.24x | 0.14x | 0.12x | 0.10x | 0.09x | 0.09x | 0.09x |
| Debt / EBITDA | 0.32x | 0.26x | 0.29x | 0.71x | 0.29x | 0.47x | 0.57x | 0.60x | 0.66x | 0.65x |
| Net Debt / EBITDA | -0.05x | -0.28x | -0.37x | 0.13x | -0.02x | -0.07x | -0.01x | 0.05x | -0.10x | -0.10x |
| Interest Coverage | 83.75x | 91.55x | 81.43x | 67.97x | 163.75x | 82.80x | 58.52x | 87.59x | 120.42x | 108.44x |
| Total Equity | 6.14B▲ 0% | 8.76B▲ 42.5% | 11.09B▲ 26.6% | 11.03B▼ 0.6% | 18.77B▲ 70.2% | 22.66B▲ 20.8% | 25.97B▲ 14.6% | 29.35B▲ 13.0% | 31.26B▲ 6.5% | 31.42B▲ 0% |
| Equity Growth % | 38.09% | 42.53% | 26.63% | -0.58% | 70.23% | 20.75% | 14.6% | 13.02% | 6.48% | 25.12% |
| Book Value per Share | 53.01 | 76.28 | 96.77 | 95.79 | 167.28 | 199.68 | 228.44 | 255.03 | 287.82 | 291.77 |
| Total Shareholders' Equity | 6.14B | 8.76B | 11.09B | 11.03B | 18.77B | 22.66B | 25.97B | 29.35B | 31.26B | 31.42B |
| Common Stock | 112K | 100K | 100K | 100K | 100K | 100K | 100K | 100K | 100K | 100K |
| Retained Earnings | 2.95B | 5.25B | 7.38B | 10.89B | 18.97B | 23.31B | 27.26B | 31.67B | 35.8B | 36.42B |
| Treasury Stock | -316.24M | -396.4M | -739.9M | -6.61B | -8.26B | -10.35B | -12.56B | -15.17B | -18.61B | -19.41B |
| Accumulated OCI | 640K | -12.3M | 21.1M | 29.3M | -26.2M | -238.8M | -80.9M | -7.9M | 77.5M | 11.9M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
REGN Cash Flow Statement
Regeneron Pharmaceuticals, Inc. (REGN) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | 1.31B | 2.2B | 2.43B | 2.62B | 7.08B | 5.01B | 4.59B | 4.42B | 4.98B | 4.98B |
| Operating CF Margin % | 22.26% | 32.71% | 37.06% | 30.81% | 44.06% | 41.2% | 35.02% | 31.13% | 34.71% | - |
| Operating CF Growth % | -12.03% | 67.94% | 10.7% | 7.74% | 170.47% | -29.18% | -8.39% | -3.78% | 12.63% | 244.58% |
| Net Income | 1.2B | 2.44B | 2.12B | 3.51B | 8.08B | 4.34B | 3.95B | 4.41B | 4.5B | 4.42B |
| Depreciation & Amortization | 145.47M | 148.2M | 210.3M | 235.9M | 286.2M | 341.4M | 421M | 482.9M | 543.7M | 540M |
| Stock-Based Compensation | 507.28M | 427.4M | 464.3M | 432M | 601.7M | 725M | 885M | 982.8M | 993.7M | 995.4M |
| Deferred Taxes | 318.81M | -140M | -130.6M | 75.6M | -147.1M | -746.4M | -837.8M | -757.3M | -785.4M | -742.3M |
| Other Non-Cash Items | 63.57M | 12.1M | -29.3M | -135M | 181.7M | 599.8M | 266.3M | -82.2M | -810.6M | -529.4M |
| Working Capital Changes | -926.53M | -697M | -200.5M | -1.5B | -1.92B | -243.3M | -94.1M | -618.3M | 532.6M | 325.6M |
| Change in Receivables | -362.72M | -268.9M | -473.1M | -1.36B | -1.93B | 707.8M | -338.8M | -554M | 498.1M | -158.5M |
| Change in Inventory | -314.19M | -387.9M | -335.5M | -529.4M | -494.3M | -696.5M | -271.7M | -619.7M | -275.3M | -96.4M |
| Change in Payables | -23.19M | 210M | 444.5M | 118.9M | 866.1M | -138.4M | 598.6M | 735.1M | 736.8M | 1.06B |
| Cash from Investing | -1.01B | -1.46B | -2.03B | -70.6M | -5.38B | -3.78B | -3.19B | -2.47B | -629.1M | -1.71B |
| Capital Expenditures | -272.6M | -383.1M | -429.6M | -614.6M | -551.9M | -590.1M | -926.4M | -755.9M | -1.21B | -1.17B |
| CapEx % of Revenue | 4.64% | 5.71% | 6.55% | 7.23% | 3.43% | 4.85% | 7.06% | 5.32% | 8.46% | - |
| Acquisitions | 0 | 1.07B | 429.6M | 614.6M | 551.9M | -230.3M | -54.9M | -16.5M | -3.3M | -3.3M |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | -26K | -1.08B | -429.6M | -614.6M | -551.9M | -1.03B | 0 | -105.6M | 0 | -48.9M |
| Cash from Financing | -24.4M | -77.1M | -252.1M | -1.97B | -1.01B | -1.01B | -1.79B | -2.2B | -3.72B | -3.43B |
| Debt Issued (Net) | 37.1M | 0 | 0 | 1.98B | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | -61.5M | 110.1M | -64.1M | -6.53B | 26.9M | -563.3M | -1.79B | -2.17B | -3.33B | -3.05B |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -370.3M | -374.3M |
| Share Repurchases | -301.7M | -191.6M | -463.9M | -6.53B | -2.68B | -2.53B | -2.94B | -3.63B | -3.97B | -3.79B |
| Other Financing | 0 | -187.2M | -188M | 2.58B | -1.03B | -445.7M | 0 | -33.4M | -10.3M | 0 |
| Net Change in Cash | 277.53M▲ 0% | 655M▲ 136.0% | 150.1M▼ 77.1% | 577M▲ 284.4% | 690.8M▲ 19.7% | 221.3M▼ 68.0% | -381.6M▼ 272.4% | -248.8M▲ 34.8% | 634.7M▲ 355.1% | -122.4M▲ 0% |
| Free Cash Flow | 1.03B▲ 0% | 1.81B▲ 75.2% | 2B▲ 10.4% | 2B▲ 0.2% | 6.53B▲ 225.9% | 4.42B▼ 32.2% | 3.67B▼ 17.1% | 3.66B▼ 0.1% | 4.08B▲ 11.3% | 4.16B▲ 0% |
| FCF Margin % | 17.62% | 27% | 30.51% | 23.58% | 40.63% | 36.35% | 27.96% | 25.8% | 28.45% | 27.85% |
| FCF Growth % | 6.21% | 75.16% | 10.4% | 0.15% | 225.9% | -32.23% | -17.11% | -0.08% | 11.35% | 37.58% |
| FCF per Share | 8.93 | 15.78 | 17.46 | 17.41 | 58.19 | 38.99 | 32.26 | 31.84 | 37.57 | 37.57 |
| FCF Conversion (FCF/Net Income) | 1.09x | 0.90x | 1.15x | 0.75x | 0.88x | 1.16x | 1.16x | 1.00x | 1.11x | 0.94x |
| Interest Paid | 18.7M | 22.3M | 25M | 23.2M | 55.8M | 53.7M | 73.1M | 52.6M | 0 | 0 |
| Taxes Paid | 754.8M | 205.6M | 342.3M | 188.1M | 1.22B | 1.5B | 870.3M | 743M | 0 | 0 |
REGN Key Ratios
Regeneron Pharmaceuticals, Inc. (REGN) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | 22.63% | 32.81% | 21.32% | 31.77% | 54.21% | 20.94% | 16.26% | 15.95% | 14.87% | 14.32% |
| Return on Invested Capital (ROIC) | 29.91% | 27.09% | 18.23% | 24.71% | 44.57% | 19.78% | 13.53% | 10.78% | 8.88% | 8.88% |
| Gross Margin | 90.76% | 91.32% | 85.13% | 84.04% | 83.05% | 85.99% | 82.89% | 86.13% | 85.35% | 84.55% |
| Net Margin | 20.41% | 36.42% | 32.26% | 41.35% | 50.25% | 35.64% | 30.14% | 31.07% | 31.41% | 29.65% |
| Debt / Equity | 0.11x | 0.08x | 0.06x | 0.24x | 0.14x | 0.12x | 0.10x | 0.09x | 0.09x | 0.09x |
| Interest Coverage | 83.75x | 91.55x | 81.43x | 67.97x | 163.75x | 82.80x | 58.52x | 87.59x | 120.42x | 108.44x |
| FCF Conversion | 1.09x | 0.90x | 1.15x | 0.75x | 0.88x | 1.16x | 1.16x | 1.00x | 1.11x | 0.94x |
| Revenue Growth | 20.82% | 14.28% | -2.28% | 29.58% | 89.14% | -24.26% | 7.76% | 8.27% | 0.99% | 5.92% |
REGN SEC Filings & Documents
Regeneron Pharmaceuticals, Inc. (REGN) SEC filings — annual & quarterly reports (10-K, 10-Q)
REGN Frequently Asked Questions
Regeneron Pharmaceuticals, Inc. (REGN) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Regeneron Pharmaceuticals, Inc. (REGN) reported $14.92B in revenue for fiscal year 2025. This represents a 61807% increase from $24.1M in 1996.
Regeneron Pharmaceuticals, Inc. (REGN) grew revenue by 1.0% over the past year. Growth has been modest.
Yes, Regeneron Pharmaceuticals, Inc. (REGN) is profitable, generating $4.42B in net income for fiscal year 2025 (31.4% net margin).
Dividend & Returns
Yes, Regeneron Pharmaceuticals, Inc. (REGN) pays a dividend with a yield of 0.47%. This makes it attractive for income-focused investors.
Regeneron Pharmaceuticals, Inc. (REGN) has a return on equity (ROE) of 14.9%. This is reasonable for most industries.
Regeneron Pharmaceuticals, Inc. (REGN) generated $4.16B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
Explore More REGN
Regeneron Pharmaceuticals, Inc. (REGN) financial analysis — history, returns, DCA and operating performance tools
Full REGN Stock Analysis
Analyst verdict, bull/bear case, risk factors and peer comparison
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates